Prelude to pancuronium and vecuronium.
The discovery of the neuromuscular blocking activity of malouetine isolated from Malouetia bequaertiana Woodson by Quevauviller and Lainé in 1960 stimulated interest in aminosteroids as potential neuromuscular blockers. Alauddin (a pharmacist) and Martin-Smith (a medicinal chemist) began research in this area, which was then taken up by pharmaceutical companies. Pure pancuronium was synthesised in 1964 by Savage and his co-workers, directed by Hewett. Pharmacologists headed by Buckett discovered that pancuronium was far more potent than d-tubocurarine and had minimal side-effects. Buckett quickly recognised the value of pancuronium, and his persistence resulted in successful clinical trials, followed by the commercial launch of pancuronium in 1968. Vecuronium was synthesised, tested and the studies published by Buckett, Hewett and Savage in 1973, but this was before anaesthetists called for a 'clean muscle relaxant' and, furthermore, it was unstable in aqueous solution. Hence, it was only promoted for clinical trials six years later.
McKenzie
A G
AG
Consultant Anaesthetist, Department of Anaesthetics, Royal Infirmary of Edinburgh, Lauriston Place, Edinburgh EH3 9YW, UK.
D049673:History, 20th Century; D006801:Humans; D003473:Neuromuscular Nondepolarizing Agents / Q000266:history*; D018733:Nicotinic Antagonists / Q000266:history*; D010197:Pancuronium / Q000266:history*; D010936:Plant Extracts / Q000266:history; D014673:Vecuronium Bromide / Q000266:history*
D003473:Neuromuscular Nondepolarizing Agents; D018733:Nicotinic Antagonists; D010936:Plant Extracts; D014673:Vecuronium Bromide; D010197:Pancuronium